{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:57:04Z","timestamp":1762459024275},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s00277-012-1588-x","type":"journal-article","created":{"date-parts":[[2012,10,20]],"date-time":"2012-10-20T09:16:09Z","timestamp":1350724569000},"page":"211-219","source":"Crossref","is-referenced-by-count":32,"title":["Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy"],"prefix":"10.1007","volume":"92","author":[{"given":"J. B.","family":"Porter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. S.","family":"Elalfy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. T.","family":"Taher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Aydinok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.-H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Sutcharitchan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Habr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"El-Beshlawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,10,21]]},"reference":[{"key":"1588_CR1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0168-8278(05)80104-7","volume":"16","author":"O Lor\u00e9al","year":"1992","unstructured":"Lor\u00e9al O, Deugnier Y, Moirand R, Lauvin L, Guyader D, Jouanolle H, Turlin B, Lescoat G, Brissot P (1992) Liver fibrosis in genetic hemochromatosis. Respective roles of iron and non-iron-related factors in 127 homozygous patients. J Hepatol 16:122\u2013127","journal-title":"J Hepatol"},{"key":"1588_CR2","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM198511143132004","volume":"313","author":"C Niederau","year":"1985","unstructured":"Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G (1985) Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 313:1256\u20131262","journal-title":"N Engl J Med"},{"key":"1588_CR3","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1053\/gast.1996.v110.pm8613000","volume":"110","author":"C Niederau","year":"1996","unstructured":"Niederau C, Fischer R, P\u00fcrschel A, Stremmel W, H\u00e4ussinger D, Strohmeyer G (1996) Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 110:1107\u20131119","journal-title":"Gastroenterology"},{"key":"1588_CR4","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood.V89.3.739","volume":"89","author":"NF Olivieri","year":"1997","unstructured":"Olivieri NF, Brittenham GM (1997) Iron-chelating therapy and the treatment of thalassemia. Blood 89:739\u2013761","journal-title":"Blood"},{"key":"1588_CR5","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.3324\/haematol.2011.047852","volume":"96","author":"KM Musallam","year":"2011","unstructured":"Musallam KM, Cappellini MD, Wood JC, Motta I, Graziadei G, Tamim H, Taher AT (2011) Elevated liver iron concentration is a marker of increased morbidity in patients with \u03b2 thalassemia intermedia. Haematologica 96:1605\u20131612","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"1588_CR6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0037-1963(01)90060-5","volume":"38","author":"NF Olivieri","year":"2001","unstructured":"Olivieri NF (2001) Progression of iron overload in sickle cell disease. Semin Hematol 38(Suppl 1):57\u201362","journal-title":"Semin Hematol"},{"key":"1588_CR7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM199907083410207","volume":"341","author":"NF Olivieri","year":"1999","unstructured":"Olivieri NF (1999) The \u03b2-thalassemias. N Engl J Med 341:99\u2013109","journal-title":"N Engl J Med"},{"key":"1588_CR8","unstructured":"Thalassaemia International Federation (2008) Guidelines for the clinical management of thalassaemia, 2nd revised edn. Available at http:\/\/www.thalassaemia.org.cy\/pdf\/Guidelines_2nd_revised_edition_EN.pdf"},{"key":"1588_CR9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1046\/j.1365-2141.2001.03195.x","volume":"115","author":"JB Porter","year":"2001","unstructured":"Porter JB (2001) Practical management of iron overload. Br J Haematol 115:239\u2013252","journal-title":"Br J Haematol"},{"key":"1588_CR10","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMct1004810","volume":"364","author":"GM Brittenham","year":"2011","unstructured":"Brittenham GM (2011) Iron-chelating therapy for transfusional iron overload. N Engl J Med 364:146\u2013156","journal-title":"N Engl J Med"},{"key":"1588_CR11","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3324\/haematol.2009.014696","volume":"95","author":"MD Cappellini","year":"2010","unstructured":"Cappellini MD, Porter JB, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, Gattermann N, Giraudier S, Lee JW, Chan LL, Lin KH, Rose C et al (2010) Tailoring iron chelation by iron intake and serum ferritin trends: the prospective multicenter EPIC study of deferasirox in 1744 patients with various transfusion-dependent anemias. Haematologica 95:557\u2013566","journal-title":"Haematologica"},{"key":"1588_CR12","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2010-11-316646","volume":"118","author":"MD Cappellini","year":"2011","unstructured":"Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, Drelichman G, Economou M, Fattoum S, Kattamis A, Kilinc Y, Perrotta S et al (2011) Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5years\u2019 follow-up. Blood 118:884\u2013893","journal-title":"Blood"},{"key":"1588_CR13","doi-asserted-by":"crossref","unstructured":"Taher A, Elalfy MS, Al Zir K, Daar S, Al Jefri A, Habr D, Kriemler-Krahn U, El-Ali A, Roubert B, El-Beshlawy A (2011) Importance of optimal dosing \u226530\u00a0mg\/kg\/d during deferasirox treatment: 2.7-year follow-up from the ESCALATOR study in patients with beta-thalassaemia. Eur J Haematol 87:355\u2013365","DOI":"10.1111\/j.1600-0609.2011.01662.x"},{"key":"1588_CR14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2141.2011.08720.x","volume":"154","author":"E Vichinsky","year":"2011","unstructured":"Vichinsky E, Bernaudin F, Forni GL, Gardner R, Hassell K, Heeney MM, Inusa B, Kutlar A, Lane P, Mathias L, Porter J, Tebbi C et al (2011) Long-term safety and efficacy of deferasirox (Exjade\u00ae) for up to 5\u00a0years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol 154:387\u2013397","journal-title":"Br J Haematol"},{"key":"1588_CR15","unstructured":"Grosse R, Jarisch A, Yamamura J, Janka G, Nielsen P, Fischer R (2011) Safe and efficient chelation by deferasirox in thalassemia major patients with low liver iron concentrations. Haematologica 96(Suppl 2):abst 0159"},{"key":"1588_CR16","doi-asserted-by":"crossref","unstructured":"Taher A, Elalfy MS, Al Zir K, Daar S, Al Jefri A, Habr D, Kriemler-Krahn U, Roubert B, El-Beshlawy A (2011) Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with beta-thalassaemia: results from the ESCALATOR study. Eur J Haematol 87:349\u2013354","DOI":"10.1111\/j.1600-0609.2011.01661.x"},{"key":"1588_CR17","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/nbm.905","volume":"17","author":"TG St Pierre","year":"2004","unstructured":"St Pierre TG, Clark PR, Chua-anusorn W (2004) Single spin-echo proton transverse relaxometry of iron-loaded liver. NMR Biomed 17:446\u2013458","journal-title":"NMR Biomed"},{"key":"1588_CR18","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2005-08-3430","volume":"107","author":"MD Cappellini","year":"2006","unstructured":"Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R et al (2006) A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with \u03b2-thalassemia. Blood 107:3455\u20133462","journal-title":"Blood"},{"key":"1588_CR19","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1600-0609.2007.00985.x","volume":"80","author":"J Porter","year":"2008","unstructured":"Porter J, Galanello R, Saglio G, Neufeld EJ, Vichinsky E, Cappellini MD, Olivieri N, Piga A, Cunningham MJ, Souli\u00e8res D, Gattermann N, Tchernia G et al (2008) Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 80:168\u2013176","journal-title":"Eur J Haematol"},{"key":"1588_CR20","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2141.2006.06455.x","volume":"136","author":"E Vichinsky","year":"2007","unstructured":"Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, Files B, Hassell K, Kelly P, Wilson F, Bernaudin F, Forni GL et al (2007) A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 136:501\u2013508","journal-title":"Br J Haematol"},{"key":"1588_CR21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s12185-011-0789-8","volume":"93","author":"V Viprakasit","year":"2011","unstructured":"Viprakasit V, Ibrahim H, Ha SY, Ho PJ, Li CK, Chan LL, Chiu CF, Sutcharitchan P, Habr D, Domokos G, Roubert B, Xue HL et al (2011) Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox. Int J Hematol 93:319\u2013328","journal-title":"Int J Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s00277-012-1588-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T13:05:11Z","timestamp":1714482311000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-012-1588-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,21]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["1588"],"URL":"https:\/\/doi.org\/10.1007\/s00277-012-1588-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,21]]}}}